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Follow-upIn this large-scale, multinational, descriptive survey, we sought to identify measures for improving treatment
outcomes for individuals with epilepsy. As a framework, questions relating speciﬁcally to each of the ﬁve steps
of the ‘patient–physician journey’, namely, patient identiﬁcation (omitted in this survey), diagnosis, choice of
drug, disease and drug information, and patient monitoring were asked. Overall, 337 physicians and 1150 pa-
tients across France, Germany, and the United States returned questionnaires. Results indicated that 16% of the
patients were initially misdiagnosed. Treatment choice was driven by efﬁcacy, safety, experience with a drug
(physician only), and convenience (patient only). Physicianswere identiﬁed as theprimary source of information
for patients, and, as expected, better informed patients were found to adhere better to their therapy than those
who were less well informed. Approximately 50% of the patients had not seen their specialist in the last year,
which indicates poor follow-up; furthermore, important topics such as seizures, treatment, and its side effects
were not discussed at every visit. Specialists, but not primary care practitioners (PCPs), consistently reported
discussing all topics more frequently than their patients, suggesting that specialists may overestimate
the clarity of their questions. There was also substantial disparity in the reasons cited for nonadherence —
patients overwhelmingly cited forgetfulness, while both PCPs and specialists cited complacency, forgetfulness,
and tolerability. We also noted a disparity between physicians and their patients, as well as between PCPs and
specialists, in their views on the impact of epilepsy on patients' lives. Our results indicate multiple opportunities
to intervene at all stages of the patient–physician journey to improve treatment outcomes. We provide practical
suggestions to achieve the most from these opportunities.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Epilepsy is one of the most common neurological disorders world-
wide, yet it remains poorly understood. It is frequently misdiagnosed,
and treatment outcomes for many people living with epilepsy are sub-
optimal. It is also associated with signiﬁcant, negative psychosocial
consequences given the perceived stigma and everyday challenges as-
sociated with living with epilepsy [1,2]. Given that the various aspects
of the disease are relatively unique to individual patients, under-
standing these unique aspects – for example, speciﬁc triggers of sei-
zures, particular needs in maintaining seizure control, and managing
the psychosocial impact – can be difﬁcult for patients and their physi-
cians alike [2].e la Recherche, 1070 Brussels,
enewegen).
. This is an open access article underThe management of epilepsy or any other chronic disease typically
represents a feedback loop composed of ﬁve steps, which could be
seen as the ‘patient–physician journey’. The ﬁve steps are the following:
patient identiﬁcation, diagnosis, choice of drug treatment, disease and
drug information, and patient monitoring (Fig. 1). Effective navigation
through the ﬁve steps of this ‘patient–physician journey’ is important
for achieving optimal outcomes.
This ﬁve-step model informed the structure and content of the
survey described here, with questions designed to elicit information
speciﬁcally relating to each of the management steps. While numerous
surveys have been conductedwith the aimof providing insight into per-
ceptions of people with epilepsy (PWE) and physicians on the speciﬁc
challenges of epilepsy and their preferences in managing the disease,
most have focused on PWE and physicians separately [2,3]. From the
patients' perspective, there is a clear preference for receiving clear infor-
mation on their disease as well as attention from the HCP to their
nonclinical needs, and opportunities for improved patient–physician
communications have been identiﬁed [4]. In an Indian survey, athe CC BY license (http://creativecommons.org/licenses/by/3.0/).
1. Patient identification
2. (Re)diagnosis
3. Treatment choice4. Disease and drug information
5. Monitoring/follow-up
Fig. 1. The ﬁve stages of the ‘patient–physician journey’.
Table 1
Survey participants.
France Germany US Total
Patients 414 472 264 1150
Physicians 113 110 114 337
Neurologist 27 61 22 110 (33%)
Epileptologist 3 9 8 20 (6%)
Primary care practitioner 83 40 84 207 (61%)
59A. Groenewegen et al. / Epilepsy & Behavior 34 (2014) 58–67signiﬁcant positive correlation between effective doctor–patient com-
munication and compliance was observed [5]. We identiﬁed one study
where both PWE and their respective physicians were included in a lin-
guistic survey study, assessing the dialogue between neurologists and
their patients during real-life visits [6]. Although it was a small-scale
study, with only 20 neurologists and 60 of their patients, encouraging
results were obtained when using a questionnaire to improve manage-
ment of side effects and common comorbid conditions.
To our knowledge, the survey described here is one the largest
of its kind. When designing the survey, it was assumed a priori that
mismatches in perceptions and expectations between patients and phy-
sicians may potentially lead to suboptimal treatment outcomes. There-
fore, the objectives of our study were to identify points of divergence
on epilepsy management between patient and physician, to indicate
the stage atwhich these divergences aremore likely to occur, to suggest
potential measures to improve patient outcome, and, ﬁnally, to identify
possible knowledge gaps.We includedboth specialists andprimary care
practitioners (PCPs) in the survey to identify opportunities for interven-
tion in different health-care settings.
2. Methods
2.1. Study design
The study employed a cross-sectional designbased on a quantitative,
descriptive survey. The survey was administered in France, Germany,
and the United States through the market research company InforMed
Insight, UK.
The three-part survey questionnaire was developed by the authors.
It was written in English and subsequently translated into German
and French. The questionnaire was back translated and tested for
content validity by local language and market research experts. The
ﬁrst two parts were completed online by physicians; part 1 pertained
to physician knowledge and practice of epilepsy, diagnosis, and
treatment while part 2 pertained to patient-speciﬁc information
and their interactions with patients. Physicians were requested to
complete the questionnaire for each individual patient seen consecu-
tively in their practice (with a maximum of seven patients during
their scheduled visits). The third part of the questionnaire was paper-
based and was completed by patients during visits to their physician's
ofﬁce. Questions were related to the patient's overall experience of liv-
ing with epilepsy, including treatment, sources of information, and in-
teractions with their physician. Patient questionnaires (part 3) were
linked to their physician's questionnaire (part 2) using an anonymous
number linkage system.
Three sets of survey questions were asked of both physicians and
patients: the impact of epilepsy on patients' lives (nine domains),
topics discussed during consultation, and adherence to therapy. Forthe question relating to the impact of epilepsy, both physicians and
patients were asked to choose a score from 1 to 7 for each of the nine
domains, with 1 indicating very little impact and 7 extremely negative
impact. Scores 5, 6, and 7 were combined to provide an overall view
on the negative impact of epilepsy on a given domain.
2.2. Ethical approval
Given the nature and content of the survey, approval by an ethics
committee was not required. Patients were free to choose to participate
or not, and thosewho chose to do sowere providedwith an information
sheet and a consent form before being asked to complete the question-
naire. The information sheet stated the purpose of the study and the
names of the sponsors. It also indicated that the survey was anonymous
and conﬁdential and that there would be no repercussions for choosing
not to participate. Physicians were not given access to the responses
of their patients.
2.3. Participants
Physicians were randomly selected from national market research
databases. Both PCPs and specialist physicians – neurologists and
epileptologists –were included in the study. Primary care practitioners
were required to see at least ﬁve PWEpermonth,while specialists were
required to see at least 10 PWE per month. The inclusion criteria for pa-
tients were the following: (1) diagnosed with epilepsy and (2) aged
18 years or older.
2.4. Data collection and analysis
Questionswere speciﬁcally based on steps 2–5 identiﬁed in the con-
ceptual framework; step 1, the identiﬁcation of new patients, was not
included in the survey as only already diagnosed patients were part of
the survey. Physicians and patientswere asked correspondingquestions
in order to identify divergent perceptions about the impact of variables
relating to quality of life, as well as the topics discussed in the last pa-
tient consultation. Data entry was carried out by InforMed Insight, and
all data were subject to two-pass veriﬁcation. Analyses were carried
out by InSites Consulting (using SPSS 19™ and STAT/SE 12™) and in-
cluded descriptive statistics, chi-squared testing, and t-tests for the
comparisons of physician and patient responses on matched survey
questions. Statistical signiﬁcance was set at the 5% level.
3. Results
3.1. Characteristics of participants
A total of 337 physicians and 1150 patients agreed to participate in
the study (Table 1). Physicians were in medical practice for a median of
16 years (4‒30 years). Of the 337 physicians included in the study, 113
were from France, 110 were from Germany, and 114 were from the
United States. Physicians reported practicing as neurologists (n = 110,
33%), epileptologists (n = 20, 6%), or PCPs (n = 207, 61%).
The median age of patients was 46 years (18‒98 years), and 50%
were female. In terms of occupation, just under half were employed
(48%, 36% full-time and 12% part-time), 19% were unemployed
60 A. Groenewegen et al. / Epilepsy & Behavior 34 (2014) 58–67(8% speciﬁcally due to their condition), 8% were students, 20% had
retired, and 4% reported ‘other’. The median time since patients had re-
ceived a diagnosis of epilepsy was 14 years (1–65 years); the majority
(61%) had received the diagnosis 10 years or more previously. Fifty-
ﬁve percent of the patients had a diagnosis of primary generalized
epilepsy, and 40% of the patients had a diagnosis of focal epilepsy. Ap-
proximately three-quarters (879/1150) of patients (76% in Germany,
71% in France, and 79% in the US) were using monotherapy to control
their seizures. Most reported good seizure control; 46% had experienced
no seizures in the past 12 months, and 44% had experienced fewer than
ﬁve seizures. Only 9% of the patients reported poor seizure control,
deﬁned as having experienced more than ﬁve seizures in the past
12 months. Almost all patients (96%) were being treated with AEDs.18%
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Fig. 2. Perspectives on the negative impact of epilepsy on various quality of life domains. The to
(b) represents specialists and their patients, and the bottom panel (c) provides a comparison bOnaverage, patients had received 1.4 other treatments (deﬁned as either
a switch inmonotherapy, as well as addition of another AED, or a change
in combination therapy) before the current treatment regimen; 35% had
one prior treatment, and 29% had two.
3.2. Impact of epilepsy on patients' lives
There were several important differences in the answers provided
by patients and physicians when asked to identify domains most
affected by epilepsy and its treatment. Overall, there was a relatively
good match in the responses given by patients and PCPs, with only
two domains of statistically signiﬁcant mismatch (both p b 0.05;
Fig. 2a). Primary care practitioners overestimated the impact of epilepsy25% 25%
29% 28%
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61A. Groenewegen et al. / Epilepsy & Behavior 34 (2014) 58–67on cognitive function— 31% (95% conﬁdence interval 28%–35%) of PCPs
reported that epilepsy had a negative impact on cognitive function,
while only 15% (95% CI 12%–18%) of patients did so. In contrast, PCPs
underestimated the negative impact of epilepsy on the ability of patients
to work or study (18% [15%–20%] vs 36% [32%–40%]).
There were a greater number of mismatched domains between
specialists and their patients compared with PCPs and their patients
(Fig. 2b). Four statistically signiﬁcantmismatch domains were identiﬁed
(all four p b 0.05). Specialists, like PCPs, overestimated the impact
of epilepsy on cognitive function (44% [40%–49%] vs 17% [13%–21%])
and underestimated the impact of epilepsy on the ability to work
or study (14% [11%–17%] vs 51% [45%–56%]). In addition, specialists
underestimated the impact of epilepsy on sleep (20% [16%–23%] vs 27%
[22%–32%]) and on leisure activities (21% [18%–25%] vs 30% [25%–34%]).
Given the differences between the responses given by PCPs and spe-
cialists, a post-hoc analysiswas conducted to further compare the views
of the two physician groups (Fig. 2c). A larger number of specialists
reported that epilepsy had a negative impact on cognitive function
compared with PCPs (44% [40%–49%] vs 31% [28%–35%]). Conversely,
more PCPs than specialists reported that epilepsy had a negative impact
on emotional well-being (24% [21%–27%] vs 19% [15%–22%]), social
relationships (25% [22%–28%] vs 19% [15%–22%]), sleep (25% [22%–
28%] vs 20% [16%–23%]), and leisure activities (29% [26%–32%] vs 21%
[18%–25%]). In terms of patient responses, there was an overall trend
for patients consulting their specialists to give higher scores on the neg-
ative impact of epilepsy on the various quality-of-life domains com-
pared with those visiting their PCPs. In one particular domain, the
ability towork/study, however, therewas substantial disparity between
their responses, with a greater percentage of patients visiting specialists
(51% [45%–56%]) reporting the negative impact of epilepsy on this
domain compared with patients visiting PCPs (36% [32%–40]).
3.2.1. Patient identiﬁcation
The design of the survey did not allow for the identiﬁcation of new
patients. Only those individuals with a conﬁrmed diagnosis of epilepsy
were included in the survey.
3.2.2. Diagnosis
Sixteen percent of patients were initially misdiagnosed. There were
no differences across physician groups or countries in terms of mean
misdiagnosis rates; however, 5% of the PCPs and 6% of the neurologists
reported misdiagnosis rates exceeding 30% in contrast to none of the
epileptologists. Patient diagnosis (by seizure type) varied considerably
by physician specialty. Primary care practitioners reported a greater
proportion of patients diagnosed with primary generalized seizures
compared with specialists (epileptologists and neurologists combined;
46% vs 27%); conversely, specialists reported a greater proportion of
patients diagnosed with focal epilepsy.
3.2.3. Treatment choice
As mentioned in Section 3.1, most patients (76.4%) were receiving
monotherapy. If response to monotherapy was deemed to be subopti-
mal, the majority of PCPs (69%) across the three countries prescribed a
second AED as monotherapy before initiating adjunctive therapy. Only
17% initiated adjunctive therapy after suboptimal response to the ﬁrst
monotherapy; 7% prescribed three monotherapy agents before initia-
tion of adjunctive therapy, while 6% reported that they do not prescribe
adjunctive therapy. Specialists had a choice of responding differently to
the question according to seizure type. For patients with focal epilepsy,
adjunctive therapy was initiated after suboptimal response to one, two,
three, four, or ≥5 monotherapies by 16%, 62%, 19%, 2%, and 1% of the
specialists, respectively. Corresponding numbers for patients with pri-
mary generalized seizures were similar; adjunctive therapy was initiat-
ed after suboptimal response to one, two, three or four monotherapies
by 14%, 62%, 22% and 1% of the specialists, respectively, while a further
1% reported that they do not prescribe adjunctive therapy.The main AED attributes driving the choice of treatment were simi-
lar for patients and physicians alike. When the physicians and patients
were asked to rank the attributes on a scale of one to seven, efﬁcacy
was the dominant factor (ranked ﬁrst by 92% of the physicians and
91% of the patients), followed by safety and tolerability (ranked second
by 91% of the physicians and 86% of the patients). ‘Experience with the
AED’ was ranked third by the physicians (81%), while ‘convenient to
take’ was ranked third by the patients (77%).
Treatment change refers to a switch inmonotherapy, addition of ad-
junctive therapy, or change in combination of AEDs. Of the patients
(65%)whohad changed treatment at least once, 38%had done sowithin
the last 24 months. Approximately one-quarter of patients (27%) re-
ported having requested treatment change at some point since starting
AED treatment. From the patients' perspective, the most common rea-
sons for treatment changewere unwanted side effects (57%) and break-
through seizures (41%). The reason physicians gavemost oftenwas lack
of efﬁcacy.
3.2.4. Disease and drug information
Patients reported obtaining information about epilepsy and treat-
ment options from a variety of sources, most often from doctors (88%),
friends and family (63%), the Internet (53%), and books (43%). Doctors
and patients agreed fairly well on how informed the patient was on
various aspects of epilepsy.
3.2.5. Monitoring and follow-up
Just under half of the patients (49%) saw their physicians on a quar-
terly basis following initial diagnosis. In the US, PCPs reported that one-
third of their patients had not been seen by a specialist in the last year,
while, in Germany and France, this applied to N50% of the patients. The
most common reasons for consultations were for a routine follow-up
(64%) or for obtaining a repeat prescription (51%). When PCPs and
specialists were asked to describe the topics they discussed during
consultations with their patients, a different pattern between them
emerged (Fig. 3). There was a good match between PCPs and their
patients in terms of the topics they reported discussing. For example,
68% of the PCPs and 69% of their patients reported discussing ‘how
they are [patients] feeling’; corresponding ﬁgures were 51% for
both PCPs and patients who reported discussing ‘seizures and symp-
toms’ (the secondmost frequent topic) and 49% and 48% for ‘epilepsy
medication’ (the third most frequent topic) during every consulta-
tion (Fig. 3A). In contrast, specialists consistently overestimated
discussing topics by a relatively large margin (Fig. 3B). The greatest
disparity in the responses given by specialists and their patients
was related to treatment tolerability/side effects; 66% of the special-
ists reported discussing this topic during all consultations, while
only 35% of their patients reported doing so.
In terms of treatment adherence, once again, there was a good
match between PCPs and their patients in the responses (Fig. 4). Prima-
ry care practitioners were aware of adherent patients; 53% of the PCPs
and 55% of their patients reported always taking their medication. In
contrast, while 60% of specialists' patients reported full adherence to
therapy, only 48% of specialists thought that their patients did so.
When both groups of physicians were asked about the reasons
for nonadherence, their responseswere similar (Figs. 5a andb). Thema-
jority of PCPs (64%) and specialists (69%) reported that the most com-
mon reason for nonadherence was complacency, followed by side
effects (61% and 51%, respectively) and forgetfulness (40% and 44%, re-
spectively). However, the most common reason patients gave for not
taking their medication was forgetfulness; 64% for patients treated by
PCPs and 66% for those treated by specialists (Figs. 5a and b), and nei-
ther complacency nor side effects were major reasons given by patients
for not taking medication.
Being well informed contributed substantially to treatment adher-
ence; 64% of the patients who felt well informed about their disease
said that they always took their medication compared with 46% of
A) Primary care practitioners and their patients
B) Specialists and their patients
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Fig. 3. Percentage of primary care practitioners (A) and specialists (B) and their respective patients reporting discussion of different topics at every follow-up visit.
62 A. Groenewegen et al. / Epilepsy & Behavior 34 (2014) 58–67those who did not feel well informed. However, physicians did not
perceive this association between being well informed and adherence.
As continuous monitoring and follow-up of patients are needed in
reassessing the impact of epilepsy management on their outcomes, pa-
tients with a low frequency of visits but demonstrating poor adherence
or reporting poor treatment results may be in need of intervention,
thereby closing the feedback loop as evident in Fig. 1. In a post-hoc anal-
ysis, this subpopulation of patients was identiﬁed based on the analysis
described in the schematic below (Fig. 6). We identiﬁed 213 patients
who fell into categories associated with poor seizure control, poor AED
tolerability, and low QoL or low satisfaction/poor adherence to treat-
ment. However, they saw their health-care provider fewer than three
times a year, and most had no treatment change in the past 2 years.
4. Discussion
Results of this large-scale, multinational survey provide substantial
insight into the impact of epilepsy and its treatment on patients' lives
from the perspective of both patients and their treating physicians.
There was substantial disparity in the views of the two groups whenevaluating the impact of epilepsy on various life domains, as well as in
their responses to questions related speciﬁcally to thepatient–physician
journey. Ourﬁndings provide the foundation for practical suggestions to
improve treatment outcomes for PWE.
4.1. Impact of epilepsy on patients' lives — divergence of patient and
physician views
Given the important impact of QoL in driving treatment decisions,
we started by looking at the impact of epilepsy on patients' lives.
Here, signiﬁcant differences were noted between patients and their
physicians in terms of the QoL domains most affected by epilepsy and
its treatment. That patients and physicians are often not in agreement
when assessing quality-of-life measures has been well documented in
the literature with respect to: measures of anxiety and depression
among cancer patients [7]; psychological concerns of cancer patients
[8]; and the assessment of QoL in patients with chronic disease [9],
and following stroke [10]. Studies in which some signiﬁcant level
of agreement was found report that disagreement increases with
the level of cognitive impairment [10] and that there is a U-shaped
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Fig. 6. Identifying patients in greatest need of intervention.
64 A. Groenewegen et al. / Epilepsy & Behavior 34 (2014) 58–67concordance between level of agreement and performance status
(deﬁned as the patient's level of functioning based on measures of ac-
tivity, ambulatory status, and need for care) [11]. Greater disagreement
has been reported on subjective measures of distress and anxiety [12],
as well as fatigue and social functioning [9].
In our survey population, we found that for both groups of patients
(those consulting their PCPs or specialists) the ability to work/study
was ranked as the most strongly impacted domain by a large margin.
Physicians, on the other hand, signiﬁcantly underestimated the impact
of epilepsy on this domain, especially specialists. While 51% of the pa-
tients reported that epilepsy had a negative impact on the ability to
work/study, only 14% of the specialists did so — a difference of 37 per-
centage points. Corresponding values were 36% and 18% for PCPs and
their patients, respectively.While the difference of 18 percentage points
is less than that observed between specialists and their patients, it still
remains an important difference. Interestingly, there was a substantial
difference in the responses of the two groups of patients as well.
More patients consulting their specialists reported that epilepsy had a
negative impact on their ability to work/study compared with those
consulting their PCPs. While this was the domain with the greatest dis-
parity in the responses given by the two groups of patients, therewas an
overall trend for patients consulting specialists to give higher scores to
the remaining domains. This observation could indicate that patients
visiting specialists hadmore severe or difﬁcult-to-control seizures com-
pared with those visiting PCPs.
For both groups of physicians, the domainmost negatively impacted
by epilepsy was cognitive function. Once again, there was a signiﬁcant
mismatch with their patients, with fewer patients overall reporting
epilepsy having a negative impact on cognitive function. Similarly, the
extent of the mismatch was greater between specialists and their
patients compared with PCPs and their patients. The impact of epilepsy
on cognition can be difﬁcult to recognize by patients, and physicians
maybe able to detect thismore clearly than patients themselves. Indeed,
as reported previously, cognitive deﬁcits tend to be underreported by
patients [13]; furthermore, patients may have different concepts of cog-
nition than physicians, which can lead to misunderstandings [14]. It is
important to note that for patients, the impact on sleep was also amain concern – especially those visiting PCPs – and it is well recognized
that epilepsy-related sleep disruption affects many aspects of life, in-
cluding cognitive function. Therefore, patients may have attributed any
cognitive impairment to sleep disturbances, rather than to the disease
or adverse effects (AEs) of AEDs.
Overall, there weremoremismatched domainswith specialists than
with PCPs (four vs two). In light of this result, we conducted a post-hoc
analysis to gain further insight into the differences between the two
groups. There were four notable differences; relative to PCPs, specialists
attributed greater impact of epilepsy on cognition, but undervalued its
impact on emotional well-being, sleep, social relationships, and leisure
activities. This ﬁnding – greater mismatch with specialists than with
PCPs – was observed in other analyses in our survey (see below).
In the second part of the analyses, participants' responses to ques-
tions related speciﬁcally to the various steps of the patient–physician
journey were evaluated. The ﬁrst step – patient identiﬁcation – was
not evaluated in this study.
4.2. Diagnostic challenges
With regard to the second step, diagnosis (rediagnosis), our survey
revealed that the mean misdiagnosis rate was 16%, which is consistent
with ﬁndings of other studies. In a study conducted in the UK, the mis-
diagnosis rate was also found to be 16% [15]; however, rates of up to
30% have also been reported [16,17]. In our survey, only PCPs and neu-
rologists reported misdiagnosis rates exceeding 30% of their currently
treated patients with epilepsy, indicating the importance of referral to
specialist centers in cases of diagnostic doubt, as well as continuing
education for physicians to review diagnostic challenges. Furthermore,
epilepsy is almost unique among common medical disorders in that
diagnosis is usually made entirely on the basis of the history [18]. This
observation emphasizes the importance of good communication skills,
which will encourage patients, family members, or friends to recount
events accurately [18]. Poor response of seizures in some patients to
their prescribed AED should also raise the index of suspicion for misdi-
agnosis, thereby prompting rediagnosis. A simple step such as repeating
the diagnostic procedure could provide an explanation for treatment
65A. Groenewegen et al. / Epilepsy & Behavior 34 (2014) 58–67resistance, resulting in treatment change and improved response for
some patients.
4.3. Factors driving choice of treatment
In our survey, therewas good agreement between patients and phy-
sicians in the factors that drive the choice for treatment. The choices
were, as expected, driven by efﬁcacy, safety, prior experience with a
drug (physician), and convenience (patient). While such factors are
clear in the case of newly diagnosed patients, ﬁndings from the ﬁnal
step, 'monitoring and follow-up', indicate that the decision-making pro-
cess when treatment change is required is not so clear-cut given the
challenges identiﬁed in patient–physician communication. As expanded
further below, factual parameters such as efﬁcacy, safety, and QoL were
not discussed adequately and, importantly, not at every visit, potentially
leading to missed opportunities to further improve patient outcome. In
a European survey of PWE and physicians conducted to gauge the level
of satisfaction with current treatment strategies, there were notable
differences between them when making treatment decisions [3]. Nota-
bly, factors related to avoiding AEs such as depression, anxiety, and be-
havioral changes and reducing titration periodwere all viewed farmore
importantly by patients than physicians. Itmust be noted, however, that
patient and physician responses were not matched in that survey. In
another study, patients were asked to identify which AED treatment
outcomes they considered most important: reduction in seizure fre-
quency was the most highly ranked treatment outcome in all three
groups included in the study (i.e., recent diagnosis, established diagno-
sis, and women of childbearing age) [19].
4.4. Sources of information
In the next step, we looked at the various sources patients used to
obtain disease-related information. While there is some evidence indi-
cating that patients consult the Internet to obtain such information,
it is important to note that patients in our survey overwhelmingly re-
ported their physicians as their primary source of information (88% vs
53% for the Internet). Other studies have also identiﬁed physicians as
themain source of information [3,20]. As expected but reassuring, none-
theless, better informed patients were found to adhere better to their
therapy compared with patients who were less well informed. These
observations indicate that physicians are ideally placed to provide valu-
able information to their patients on all aspects of the disease, enabling
them to manage their condition more effectively. However, physicians
rarely have time to provide adequate information — in this survey, the
average consultation time was 32 min for newly diagnosed patients
and 17 min for follow-up visits. Average time spent in consultation,
by region, for those with newly diagnosed epilepsy was 29, 30, and
36 min in France, Germany, and the US, respectively; corresponding
values for follow-up consultations were on average 17, 15, and 20 min.
In the patient–physician survey by Gilliam and colleagues, the mean
consultation time was even shorter at 12 min [6]. Given the limited
amount of time available during consultations, it would be helpful if
physicians could guide their patients to validated sources of information,
whether on the Internet, or printed material, or other health-care pro-
viders such as specialist nurses and counselors. In this respect, physi-
cians should perhaps see themselves as the gatekeepers, rather than
providers of information. Yet, in this survey, only 6% of the physicians
mentioned having an epilepsy nurse as support.
The Internet may be a valuable resource for some patients, and a
study to determine the user proﬁle of those who ﬁnd it most useful
would be informative. Also, whether the use of the Internet results
in greater dissatisfaction with treatment, or whether dissatisﬁed pa-
tients use the Internet more, could not be determined. However, it is
clear that the use of online resources can be of beneﬁt to some PWE
(see below).4.5. Monitoring and follow-up
Our main ﬁndings focus on the ﬁfth step, given that epilepsy is a
chronic condition and necessitates long-term follow-up. Consultations
provide the opportunity for patients and physicians to review the status
quo and to either maintain it or change it. However, our ﬁndings reveal
manymissed opportunities. Foremost, approximately 50% of the patients
in this study had not seen their specialist in the last year, which indicates
inadequate follow-up. It is not clear if follow-up programs, information,
and/or instructions in epilepsy are as well developed as those for other
serious chronic diseases, such as diabetes and cancer. It is advisable that
PCPs and patients agree on a revisit protocol and an understanding of
when to recontact; it is not sufﬁcient to ask patients to call if they are hav-
ing problemswithout deﬁning the problems that need physician's atten-
tion. Notably, we identiﬁed a not insigniﬁcant subgroup of patients (19%)
who were in need of intervention. These patients were identiﬁed based
on their reports of poor seizure control, poor AED tolerability, or low
QoL, as well as low satisfaction/poor adherence to treatment. However,
they saw their health-care provider fewer than three times a year, and
most had no treatment change in the past 2 years.
4.5.1. Patient–physician dialogue
Our ﬁndings also shed light on why opportunities are missed.When
asked to report discussion topics during consultations, important topics
such as seizures and treatment side effects were not discussed at every
visit.
Therewere pronounced disparities between specialists and their pa-
tients in their perception of topics discussed in all consultations but not
betweenPCPs and their patients. Specialists substantially overestimated
discussing important topics such seizures and symptoms, medication,
and its side effects. Quality of life was the only topic reported by a sim-
ilar but small proportion of specialists and their patients to be discussed
at every consultation (32% and 30%, respectively). In contrast, there was
an excellent match between PCPs and their patients in the reporting
of discussion topics. The greatest disparity between their responses
related to QoL, where interestingly patients, rather than the PCPs,
overestimated discussing this topic at every visit (42% and 35%, respec-
tively). Despite the good match, the proportion of both PCPs and pa-
tients reporting discussing speciﬁc topics was much smaller than that
of both specialists and their patients. Fewer PCPs and their patients re-
ported discussing ‘how are you feeling’, seizures and symptoms, medi-
cation, and its side effects at every consultation compared with
specialists and their patients. These observations suggest that specialists
may overestimate the clarity of their questions, that PCPsmay not ques-
tion their patients enough, and that some patients take in information
on certain topics less well than on others.
In the aforementioned European survey, PWE and physicians also
had differing views on what was discussed during consultations [3].
Asking clear, unambiguous questions such as “how many seizures
have you had since we last met” is clearly preferable to asking the ques-
tion “how have you been”. Indeed, the importance of these missed
opportunities is such that documentation of seizure type and frequency
is the ﬁrst of eight epilepsy quality measures developed by the
American Academy of Neurology [21]. According to the authors, when
patients report that they are “doing well,” they may not mean that
they are seizure-free, but rather that they have the same seizure fre-
quency as before. In a survey of PWE using a web-based epilepsy com-
munity, 60% of the respondents cared for by PCPs reported that their
physician asked themhowmany seizures they had (for each type of sei-
zure they experience) since their last visit [22]. Corresponding ﬁgures
for epileptologists and neurologists were 91% and 94%, respectively.
Therefore, it is imperative to ask PWE direct questions in unambiguous
terms in order to assess current seizure control and other important
issues such as the impact of AEs of treatment. People with epilepsy
have been reported to be reluctant to discuss AEs with their physicians
and relied on them to raise such issues; correspondingly, physicians
Table 2
Potential interventions to improve outcomes among individuals with epilepsy at the
various steps of the patient–physician journey.
Diagnosis/rediagnosis
• Continuing education — review of diagnostic challenges
• Improvement of communication skills in order to encourage patients to recount
events accurately
• Poor response to prescribed therapy — index of suspicion for misdiagnosis should
prompt rediagnosis
Treatment — drug choice and adaptation
• Discuss factual parameters such as treatment efﬁcacy, tolerability, and impact on
quality of life at every visit to determine whether treatment change is required
Disease and drug information
• Given the lack of time during consultations, physicians should be the gatekeepers
rather than providers of information — they should guide their patients in terms
of the following:
○ Validated sources of information whether on the Internet or print material
○ Other health-care providers such as specialist nurses and counselors
Monitoring and follow-up
• Agree on a revisit protocol and an understanding of when to contact; it is not
sufﬁcient to ask patients to call if they are having problems without deﬁning the
problems that need physician's attention
• Provide patients with the opportunity and assistance to learn how to recognize
issues and problems with their treatment
• Ask direct, clear questions in unambiguous terms in order to assess current
seizure control and other important issues such as the impact of adverse effects of
treatment
• Developing a speciﬁc checklist to complete rather than a ‘free-ﬂoating’ discussion
could be of value
• Forgetfulness has been cited as the most frequent reason for nonadherence;
however, it is important to determine why patients forget to take their medicine
• Nonadherence is rarely due to a single factor; therefore, even if one factor is
successfully addressed, the problem may still persist. Addressing the issues related
to each of these factors is necessary if adherence is to be improved
• Encourage self-management
○ Explain clearly that self-management is a partnership between the patient and
the health-care provider — while epilepsy requires medical services and assis-
tance from a clinician, the expert in the day-to-day challenges of management is
the patient
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complete rather than a ‘free-ﬂoating’ discussion could be of value, as
would providing patients with the opportunity and assistance to learn
how to recognize issues and problems with their treatment [23,24].
4.5.2. Identifying and addressing reasons for nonadherence
Another important aspect of monitoring patients with chronic
diseases is to ascertain their adherence to their therapeutic regimen.
Treatment adherence is essential for preventing breakthrough seizures
and potentially life-threatening events such as status epilepticus. In
the RANSOM study, nonadherence was associated with a greater than
threefold increased risk of mortality compared with adherence [25].
Consequently, identifying and addressing reasons for nonadherence is
an essential aspect of the patient–physician dialog.
In our survey, PCPs and their patients mostly agreed on the extent
but not on the reasons for treatment nonadherence, while specialists
and their patients agreed on neither the extent nor the reasons. Patients
overwhelmingly cited forgetfulness, while physicians cited complacen-
cy, forgetfulness, and tolerabilitymost frequently. The issue of treatment
adherence in epilepsy is complex, given that PWE only experience
symptoms (i.e., seizures) sporadically but are required to take medica-
tions on a daily basis for many years [26]. Since the consequences
of nonadherence may not appear immediately, PWE may conclude
erroneously that rigorous adherence to their treatment regimen is not
important [26]. Furthermore, nonadherence can lead to detrimental
clinical decisions if the reasons for nonadherence are not thoroughly
and thoughtfully questioned, e.g., changing a drug that could have po-
tentially been very effective or increasing the dose leading to severe
AEs or even to a misdiagnosis of drug-resistant epilepsy [27]. The
reasons or predisposing factors for nonadherence are numerous; even
variation in the appearance of tablets has been shown to be signiﬁcantly
associated with nonadherence in epilepsy [28]. Forgetfulness has been
cited as the most frequent reason for nonadherence in epilepsy and in
chronic diseases in general [29–32]. However, it is important to deter-
mine why patients forget. Nonadherence is rarely due to a single factor;
therefore, even if one factor is successfully addressed, the problem
may still persist. Addressing the issues related to each of these factors
is necessary if patients' adherence to therapies is to be improved
[33]. According to the World Health Organization, the mismatch be-
tween the patients' ‘readiness’ and the physicians' attempts at interven-
tion means that patients will most likely not adhere to prescribed
therapy [33]. Therefore, the role of physicians in ensuring adherence is
paramount — they need to be able to assess the risk of nonadherence,
evaluate the patient's readiness to adhere, advise them on how to do
so, and follow up on their progress at every contact [33].
As with many other chronic diseases, self-management in epilepsy
should be encouraged. Self-management should be viewed as a partner-
ship between the person and the health-care provider— in this partner-
ship, the patient recognizes that chronic conditions require medical
services and assistance from a clinician, and the health-care provider
recognizes that the expert in the day-to-day challenges of management
is the patient [34]. Physicians should involve themselves in the process
of self-management, monitoring, and follow-up as this may potentially
provide opportunities to adapt treatment and encourage behavioral
improvements.
4.6. Study limitations
The major limitation of the study is that the survey reports subjec-
tive perceptions of QoL and did not employ objective measures or stan-
dardized scales. Comparisons of subjective assessments (i.e., those of
patients) with the potentially more objective assessments (i.e., those
of physicians) should not be used to suggest that one is more valid
than the other. Patients have their personal experience and perhaps
that of acquaintances, friends, and family as points of reference, whereas
physicians have the broader perspective resulting from seeing manypatientswith epilepsy. To illustrate this, physicians rated cognitive func-
tioning as being more affected by epilepsy than did patients. Physicians
may be able to observe the effect on cognitive function more clearly
compared with patients themselves. Conversely, ability to work/study
appeared to be the main concern of patients. Additionally, the survey
was administered in high-income countries; as such, the results may
lack transferability to low- ormedium-income country contexts. Finally,
the Hawthorn effect (placebo effect) of the survey itself cannot be ruled
out both in the case of physicians and patients— in the case of patients,
the mere fact that they were participating in the study may have im-
proved their subjective assessment of the outcomes of interest; alter-
nately, the fact that physicians were similarly a part of the study may
have altered their perceptions of their patients' outcomes.
5. Conclusions
The results of this survey reveal many missed opportunities to im-
prove outcomes for PWE starting from diagnosis (Table 2). One in six
patients were found to be initially misdiagnosed; since timely and accu-
rate diagnosis is the ﬁrst step toward managing the disorder, education
on the diagnosis of epilepsy and protocolled disease status monitoring
for physicians could contribute to improved patient outcomes. The
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patients— efﬁcacy, safety, experience with a drug (physician), and con-
venience (patient). While such factors are clear in the case of newly di-
agnosed patients, important treatment decisions for patients who have
been living with the condition may not be so clear for a number of rea-
sons: poor follow-up, lack of clarity in the discussions/questions during
follow-up visits, anddisparity in the reasons provided for nonadherence
to treatment.
Although not a primary objective of this study, our results also
showed disparity between PCPs and specialists in their views on the im-
pact of epilepsy on patients' lives. Primary care practitioners reported a
greater overall negative impact on patients' lives compared with spe-
cialists. Primary care practitioners also appeared to be more ‘in tune’
with patients, as demonstrated by the almost perfect match between
their answers and their patients when asked about topics of discussion
during visits, as well as better view on the extent of treatment adher-
ence by patients. Based on these observations, PCPs appear to have
a more holistic view of their patients' condition. A close interaction
between PCPs and specialists could lead to a greater improvement in
some dimensions of the QoL of patients and the overall quality of care.
In conclusion, there are structural opportunities for intervention
identiﬁed in every step of the patient–physician journey, and physicians
are encouraged to take a step back in their daily practice to see how
best these interventions can be implemented by the team. It is of
fundamental importance to recognize that the successful treatment
of PWE depends not only on the time spent in the doctor's ofﬁce but
also on appropriate monitoring and follow-up, as well as a detailed
plan and protocol for communication between patients and physicians
over the long term.
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